10x Genomics, Inc.

NasdaqGS:TXG 株式レポート

時価総額：US$5.9b

10x Genomics 配当と自社株買い

配当金 基準チェック /06

10x Genomics配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-0.1%

バイバック利回り

総株主利回り-0.1%
将来の配当利回り0%
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

ナラティブ更新 • Jul 23

TXG: Cancer Collaboration And Tools Strength Will Support Balanced Outlook

The analyst price target for 10x Genomics has been raised from $45.00 to $50.00. Analysts generally point to higher sector multiples, expectations that single cell and the Atera platform could support future demand, and updated earnings models ahead of upcoming results as key reasons for the change.
ナラティブ更新 • Jul 09

TXG: Cancer Collaboration And Spatial Rollout Will Support More Constructive Outlook

Analysts have lifted the 10x Genomics fair value estimate from $40.00 to $45.00, reflecting higher Street price targets, including recent moves to $37 at Morgan Stanley, $40 at Barclays, and $45 at Citi. These changes are supported by updated earnings models and growing interest in life science tools.
ナラティブ更新 • Jun 25

TXG: Multiomic Cancer Collaboration And Spatial Launch Plans Will Support Bullish Outlook

Analysts have lifted the 10x Genomics fair value estimate to $40 from $32, reflecting a higher Street price target and modest tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions in recent research updates across the tools sector. Analyst Commentary Recent research on 10x Genomics reflects a cluster of bullish adjustments to price targets and ratings across the life science tools space, with several bullish analysts flagging the stock as a relative bright spot within healthcare tools and diagnostics.
ナラティブ更新 • Jun 11

TXG: Multiomic Expansion And Spatial Launch Plans Will Shape Fairly Valued Outlook

Analysts have lifted their price targets on 10x Genomics by a range of $2 to $10, reflecting updated views on the stock. These revisions are now feeding into this valuation narrative and refined assumptions around discount rate, revenue growth, profit margins, and future P/E.
Seeking Alpha • Jun 10

10x Genomics: Temporary Pain, Long-Term Gain As Atera Rollout Approaches

Summary 10x Genomics is re-rated neutral after a 186% rally, with a $30 price target implying limited near-term upside. TXG's fundamentals improved: Q1 gross margin expanded to 70%, GAAP net loss narrowed by 61%, and operating expenses declined 15%. The Atera spatial platform offers significant long-term revenue potential, though near-term cannibalization and execution risks could cap upside. Balance sheet remains robust with $540 million cash and no debt, supporting future growth and product rollouts. Read the full article on Seeking Alpha
ナラティブ更新 • May 28

TXG: Spatial Consumables And Spatial Partnerships Will Support Atera-Led Upside In 2026

Analysts have lifted their price targets on 10x Genomics by single digit dollar amounts, citing more constructive views on revenue growth, margins and the competitive setup. This feeds into a refreshed valuation framework even as the internal fair value estimate stays at $32.00 per share.
分析記事 • May 13

Analysts Are Updating Their 10x Genomics, Inc. (NASDAQ:TXG) Estimates After Its First-Quarter Results

10x Genomics, Inc. ( NASDAQ:TXG ) just released its latest quarterly results and things are looking bullish. Revenues...
ナラティブ更新 • May 12

TXG: 2026 Academic Demand Weakness Will Challenge Elevated Expectations

Analysts have raised 10x Genomics' consolidated price target by several dollars into the mid $20s, citing improving expectations for revenue growth, modestly higher profit margins, and recent research that points to steady new product adoption and a more favorable competitive environment. Analyst Commentary Recent Street research on 10x Genomics has largely centered on a series of price target revisions tied to product adoption trends, funding visibility and the mix between instruments and consumables.
ナラティブ更新 • Apr 21

TXG: Spatial Consumables Strength Will Offset Instrument Softness In 2026

The analyst price target for 10x Genomics has shifted from about $24 to $32, with analysts pointing to recent target hikes across multiple firms that reflect updated views on product adoption, competitive positioning in single cell, and mixed trends across instrument and consumables demand. Analyst Commentary Recent research shows a cluster of bullish analysts increasing their price targets on 10x Genomics, as well as at least one upgrade, pointing to a more constructive stance on the story.
ナラティブ更新 • Apr 06

TXG: Spatial Consumables And New Product Uptake Will Shape 2026 Outlook

Analysts have raised their average price target on 10x Genomics from about $18 to roughly $24, citing solid new product adoption, a favorable competitive setup in single cell, and expectations that pressure in instruments and single cell consumables could be partly offset by growth in spatial consumables. Analyst Commentary Recent research updates show a cluster of bullish analysts lifting price targets on 10x Genomics, with new targets cited at about $18, $20 and $25.
ナラティブ更新 • Mar 23

TXG: New Product Uptake And Funding Uncertainty Will Shape 2026 Setup

Analysts have nudged the blended price target for 10x Genomics higher, with recent moves such as Stifel lifting its target to $25 from $20 and UBS taking its target to $20 from $14, citing solid new product adoption, a favorable single cell competitive setup, and mixed but evolving trends in academic funding, instruments, and consumables. Analyst Commentary Recent research points to a more balanced view on 10x Genomics, with higher price targets reflecting confidence in certain growth drivers alongside caution around funding visibility and product mix.
ナラティブ更新 • Mar 07

TXG: 2026 Academic Weakness And Pricing Pressure Will Test Elevated Expectations

Analysts have inched up their price targets on 10x Genomics, with moves such as $14 to $20 at UBS, $15 to $18 at TD Cowen and $20 to $25 at Stifel. These changes reflect a mix of confidence in new product adoption, a favorable single cell competitive setup, and expectations that spatial consumables can help offset pressure in single cell consumables and softer academic instrument demand.
ナラティブ更新 • Feb 21

TXG: 2026 Academic Demand And Pricing Pressures Will Challenge Rich Sentiment

The analyst price target for 10x Genomics has increased from $14 to $17, as analysts factor in updated assumptions for faster revenue growth, slightly higher margins, and a higher future P/E multiple, despite ongoing caution around academic demand and single cell consumables. Analyst Commentary Recent street research on 10x Genomics points to a mixed setup, with price target changes reflecting both interest in the story and clear caution around execution, product mix, and end market trends.
ナラティブ更新 • Feb 07

TXG: Higher Q4 Bar And Soft 2026 Setup May Cap Upside

Analysts have nudged their price target on 10x Genomics up to $18 from $15, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that they view as better aligned with their latest outlook on the life science tools space. Analyst Commentary Recent research points to a more balanced stance on 10x Genomics, with the higher price target reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E while the rating remains neutral.
分析記事 • Jan 24

10x Genomics, Inc. (NASDAQ:TXG) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Despite an already strong run, 10x Genomics, Inc. ( NASDAQ:TXG ) shares have been powering on, with a gain of 34% in...
ナラティブ更新 • Jan 23

TXG: ARK Buying And Soft 2026 Outlook Will Restrain Upside Potential

Analysts have nudged their 10x Genomics price target higher to about $18, up from around $17.36. This reflects slightly updated fair value, discount rate, revenue growth, profit margin, and future P/E assumptions, alongside recent Street research that includes an $18 target and continued institutional interest.
ナラティブ更新 • Jan 08

TXG: Q4 Guidance And 2026 Outlook Will Likely Pressure Rich Sentiment

Analysts have raised their fair value estimate for 10x Genomics from US$9.00 to US$14.00, citing higher assumed revenue growth, a richer future P/E multiple, and recent Street research that highlights an increased price target in the life science tools space. Analyst Commentary Recent research in the life science tools space has highlighted a cautious tone around near term expectations for 10x Genomics, even as some price targets have been adjusted.
ナラティブ更新 • Dec 25

TXG: ARK Buying And Platform Advances Will Shape Future Risk Reward Balance

Analysts have raised their price target on 10x Genomics by about 5 percent to reflect a modestly higher fair value estimate of approximately 17.36 dollars per share. This change is supported by slightly improved long term margin expectations and renewed institutional buying interest highlighted by recent ARK Investment purchases.
ナラティブ更新 • Dec 11

TXG: ARK Buying And Product Advances Will Shape Balanced Risk Reward Outlook

Analysts have nudged their price target for 10x Genomics slightly higher, from approximately 16.36 dollars to 16.57 dollars, citing incremental improvements in long term growth assumptions and renewed institutional interest following sizable recent share purchases. Analyst Commentary Analyst reaction to the latest moves in 10x Genomics stock has been mixed, with many highlighting both the opportunities created by recent institutional buying and the ongoing execution risks that could affect the company’s valuation trajectory.
ナラティブ更新 • Nov 27

TXG: ARK Share Purchase Will Not Offset Persistent Market Pressure

Analysts have modestly raised their fair value estimate for 10x Genomics from $15.86 to $16.36 per share. This change reflects expectations of improved revenue growth, a resilient market position, and support from recent institutional investment activity, despite ongoing macroeconomic headwinds.
分析記事 • Nov 14

There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump

10x Genomics, Inc. ( NASDAQ:TXG ) shareholders would be excited to see that the share price has had a great month...
ナラティブ更新 • Nov 09

TXG: Institutional Interest And New Assay Expected To Influence Future Performance

Analysts have increased their price target for 10x Genomics from $15.08 to $15.86 per share. They cite improvements in revenue growth and profit margin as key factors behind the upward revision.
ナラティブ更新 • Aug 08

Advanced Genomics Tools Will Shape Future Precision Medicine

Despite a decline in consensus revenue growth forecasts, a rising future P/E suggests increased optimism for profitability or valuation, leading to a higher analyst price target for 10x Genomics. What's in the News 10x Genomics guided Q3 2025 revenue to $140–$144 million, noting an impact from $4.0 million in China customer purchases pulled forward due to anticipated tariff changes.
User avatar
新しいナラティブ • Mar 23

Chan Zuckerberg Initiative Partnership Will Drive Future Demand

Strategic introduction of lower-priced products and sales reorganization are poised to drive volume growth and enhance market share in biopharma and academia.

決済の安定と成長

配当データの取得

安定した配当: TXGの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: TXGの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

10x Genomics 配当利回り対市場
TXG 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (TXG)n/a
市場下位25% (US)1.3%
市場トップ25% (US)4.1%
業界平均 (Life Sciences)0.6%
アナリスト予想 (TXG) (最長3年)0%

注目すべき配当: TXGは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: TXGは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: TXGの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: TXGが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/07/27 18:26
終値2026/07/24 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

10x Genomics, Inc. 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22

アナリスト機関
Luke SergottBarclays
Michael RyskinBofA Global Research
Kyle MiksonCanaccord Genuity